Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

INTRODUCTION: Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III ALCANZA study. METHODS: Baseline CD30...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youn H., Prince, H. Miles, Whittaker, Sean, Horwitz, Steven M., Duvic, Madeleine, Bechter, Oliver, Sanches, Jose A., Stadler, Rudolf, Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Eradat, Herbert, Pinter-Brown, Lauren C., Ortiz-Romero, Pablo L., Akilov, Oleg E., Trotman, Judith, Taylor, Kerry, Weichenthal, Michael, Walewski, Jan, Fisher, David, McNeeley, Marise, Gru, Alejandro A., Brown, Lisa, Palanca-Wessels, M. Corinna, Lisano, Julie, Onsum, Matthew, Bunn, Veronica, Little, Meredith, Trepicchio, William L., Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347228/
https://www.ncbi.nlm.nih.gov/pubmed/33794441
http://dx.doi.org/10.1016/j.ejca.2021.01.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347228/
https://www.ncbi.nlm.nih.gov/pubmed/33794441
http://dx.doi.org/10.1016/j.ejca.2021.01.054

Ejemplares similares